Limits...
Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial.

Ng NT, Heesch KC, Brown WJ - Arthritis Res. Ther. (2010)

Bottom Line: During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05).No significant differences were found between walking groups.In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms.

View Article: PubMed Central - HTML - PubMed

Affiliation: The University of Queensland, School of Human Movement Studies, Blair Drive, St Lucia Campus, Brisbane, Queensland 4072, Australia. norman.ng@uqconnect.edu.au

ABSTRACT

Introduction: Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological therapies. Although walking is commonly recommended for reducing pain and increasing physical function in people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms and physical activity participation in people with mild to moderate hip or knee OA.

Methods: Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg glucosamine sulphate per day for 6 weeks, after which they began a 12-week progressive walking program, while continuing to take glucosamine. They were randomized to walk 3 or 5 days per week and given a pedometer to monitor step counts. For both groups, step level of walking was gradually increased to 3000 steps/day during the first 6 weeks of walking, and to 6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, physical function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness and physical function. Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week follow-ups. The Mann Whitney Test was used to examine differences in outcome measures between groups at each assessment, and the Wilcoxon Signed Ranks Test was used to examine differences in outcome measures between assessments.

Results: During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05). Between the start of the walking program (Week 6) and the final follow-up (Week 24), further improvements were seen in these outcomes (P < 0.05) although most improvements were seen between Weeks 6 and 12. No significant differences were found between walking groups.

Conclusions: In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms. A more robust study with a larger sample is needed to support these preliminary findings.

Trial registration: Australian Clinical Trials Registry ACTRN012607000159459.

Show MeSH

Related in: MedlinePlus

Compliance with the Stepping Out program. (a) The percentage of participants who complied with the number of 'walking' days per week of the walking program (Weeks 7 to 18 of the study). (b) Mean number of steps walked each 'walking' day during the 12-week Stepping Out program (Weeks 7 to 18 of the study).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2875659&req=5

Figure 3: Compliance with the Stepping Out program. (a) The percentage of participants who complied with the number of 'walking' days per week of the walking program (Weeks 7 to 18 of the study). (b) Mean number of steps walked each 'walking' day during the 12-week Stepping Out program (Weeks 7 to 18 of the study).

Mentions: For each week of the Stepping Out program (Weeks 7 to 18), most participants in both groups were compliant with walking the number of 'walking days' called for in the protocol (i.e., they walked the prescribed three or five days per week), but compliance was higher in the three-day walking group than in the five-day walking group (Figure 3). Among participants in the three-day walking group, there was 100% compliance with walking three days per week during Weeks 8, 9, 12, 15, and 18. Among participants in the five-day walking group, compliance ranged from 93% (Week 7) to 58% (Week 16) during the 12-week walking program. The mean number of days walked throughout the 12 weeks was also computed. No significant difference in number of days walked were found between groups although there was a trend in significance (P = 0.06). On average, participants in the three-day group walked three days per week (mean days/week = 3.07 (standard deviation (SD) 0.82) days), but participants in the five-day group did not walk five days per week (mean days/week = 3.93 (SD 1.09) days).


Efficacy of a progressive walking program and glucosamine sulphate supplementation on osteoarthritic symptoms of the hip and knee: a feasibility trial.

Ng NT, Heesch KC, Brown WJ - Arthritis Res. Ther. (2010)

Compliance with the Stepping Out program. (a) The percentage of participants who complied with the number of 'walking' days per week of the walking program (Weeks 7 to 18 of the study). (b) Mean number of steps walked each 'walking' day during the 12-week Stepping Out program (Weeks 7 to 18 of the study).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2875659&req=5

Figure 3: Compliance with the Stepping Out program. (a) The percentage of participants who complied with the number of 'walking' days per week of the walking program (Weeks 7 to 18 of the study). (b) Mean number of steps walked each 'walking' day during the 12-week Stepping Out program (Weeks 7 to 18 of the study).
Mentions: For each week of the Stepping Out program (Weeks 7 to 18), most participants in both groups were compliant with walking the number of 'walking days' called for in the protocol (i.e., they walked the prescribed three or five days per week), but compliance was higher in the three-day walking group than in the five-day walking group (Figure 3). Among participants in the three-day walking group, there was 100% compliance with walking three days per week during Weeks 8, 9, 12, 15, and 18. Among participants in the five-day walking group, compliance ranged from 93% (Week 7) to 58% (Week 16) during the 12-week walking program. The mean number of days walked throughout the 12 weeks was also computed. No significant difference in number of days walked were found between groups although there was a trend in significance (P = 0.06). On average, participants in the three-day group walked three days per week (mean days/week = 3.07 (standard deviation (SD) 0.82) days), but participants in the five-day group did not walk five days per week (mean days/week = 3.93 (SD 1.09) days).

Bottom Line: During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05).No significant differences were found between walking groups.In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms.

View Article: PubMed Central - HTML - PubMed

Affiliation: The University of Queensland, School of Human Movement Studies, Blair Drive, St Lucia Campus, Brisbane, Queensland 4072, Australia. norman.ng@uqconnect.edu.au

ABSTRACT

Introduction: Management of osteoarthritis (OA) includes the use of non-pharmacological and pharmacological therapies. Although walking is commonly recommended for reducing pain and increasing physical function in people with OA, glucosamine sulphate has also been used to alleviate pain and slow the progression of OA. This study evaluated the effects of a progressive walking program and glucosamine sulphate intake on OA symptoms and physical activity participation in people with mild to moderate hip or knee OA.

Methods: Thirty-six low active participants (aged 42 to 73 years) were provided with 1500 mg glucosamine sulphate per day for 6 weeks, after which they began a 12-week progressive walking program, while continuing to take glucosamine. They were randomized to walk 3 or 5 days per week and given a pedometer to monitor step counts. For both groups, step level of walking was gradually increased to 3000 steps/day during the first 6 weeks of walking, and to 6000 steps/day for the next 6 weeks. Primary outcomes included physical activity levels, physical function (self-paced step test), and the WOMAC Osteoarthritis Index for pain, stiffness and physical function. Assessments were conducted at baseline and at 6-, 12-, 18-, and 24-week follow-ups. The Mann Whitney Test was used to examine differences in outcome measures between groups at each assessment, and the Wilcoxon Signed Ranks Test was used to examine differences in outcome measures between assessments.

Results: During the first 6 weeks of the study (glucosamine supplementation only), physical activity levels, physical function, and total WOMAC scores improved (P < 0.05). Between the start of the walking program (Week 6) and the final follow-up (Week 24), further improvements were seen in these outcomes (P < 0.05) although most improvements were seen between Weeks 6 and 12. No significant differences were found between walking groups.

Conclusions: In people with hip or knee OA, walking a minimum of 3000 steps (approximately 30 minutes), at least 3 days/week, in combination with glucosamine sulphate, may reduce OA symptoms. A more robust study with a larger sample is needed to support these preliminary findings.

Trial registration: Australian Clinical Trials Registry ACTRN012607000159459.

Show MeSH
Related in: MedlinePlus